PURPOSE: Survivin, an inhibitor of apoptosis protein and a cell cycle regulator, has been detected in the majority of human cancers. Five splice variants (survivin, survivin-2alpha, survivin-2B, survivin-3B, and survivin-DeltaEx3) have been identified; their expressions have been investigated here. METHODS: By means of RT real-time PCR and immunohistochemistry, we have evaluated survivin isoform expressions at both mRNA and protein levels in human normal oral tissue, precancerous lesions, and oral squamous cell carcinoma (OSCC). Their correlations with the pathological findings have also been analyzed. RESULTS: Expression levels of all survivin transcript variants were markedly elevated in OSCC when compared to normal tissues. One-way analysis of variance (ANOVA) revealed highly significant up-regulation of survivin (P = 0.001), survivin-DeltaEx3 (P = 0.001) and survivin-2B (P = 0.004), whereas survivin-3B showed a minor increase in OSCC compared to normal mucosa. CONCLUSIONS: Our findings suggest that survivin isoforms deregulation may have significant implications in tumor aggressiveness and prognosis.
PURPOSE: Survivin, an inhibitor of apoptosis protein and a cell cycle regulator, has been detected in the majority of humancancers. Five splice variants (survivin, survivin-2alpha, survivin-2B, survivin-3B, and survivin-DeltaEx3) have been identified; their expressions have been investigated here. METHODS: By means of RT real-time PCR and immunohistochemistry, we have evaluated survivin isoform expressions at both mRNA and protein levels in human normal oral tissue, precancerous lesions, and oral squamous cell carcinoma (OSCC). Their correlations with the pathological findings have also been analyzed. RESULTS: Expression levels of all survivin transcript variants were markedly elevated in OSCC when compared to normal tissues. One-way analysis of variance (ANOVA) revealed highly significant up-regulation of survivin (P = 0.001), survivin-DeltaEx3 (P = 0.001) and survivin-2B (P = 0.004), whereas survivin-3B showed a minor increase in OSCC compared to normal mucosa. CONCLUSIONS: Our findings suggest that survivin isoforms deregulation may have significant implications in tumor aggressiveness and prognosis.
Authors: Patricia Grabowski; Sonja Griss; Christian N Arnold; Dieter Hörsch; Rüdiger Göke; Rudolf Arnold; Berhard Heine; Harald Stein; Martin Zeitz; Hans Scherübl Journal: Neuroendocrinology Date: 2005-04-04 Impact factor: 4.914
Authors: A Islam; H Kageyama; N Takada; T Kawamoto; H Takayasu; E Isogai; M Ohira; K Hashizume; H Kobayashi; Y Kaneko; A Nakagawara Journal: Oncogene Date: 2000-02-03 Impact factor: 9.867
Authors: Kostyantyn Krysan; Farrukh H Merchant; Li Zhu; Mariam Dohadwala; Jie Luo; Ying Lin; Nathalie Heuze-Vourc'h; Mehis Põld; David Seligson; David Chia; Lee Goodglick; Hejing Wang; Robert Strieter; Sherven Sharma; Steven Dubinett Journal: FASEB J Date: 2003-11-03 Impact factor: 5.191
Authors: Salvatore de Maria; Lorenzo Lo Muzio; Alessandra Braca; Paolo Rega; Amalia Cassano; Angela Vinella; Ruggiero Fumarulo; Rosario Serpico; Ernesto Farina; Vittoria Metafora; Giuseppe Pannone; Gian Pietro Ravagnan; Salvatore Metafora; Corrado Rubini; Maria Carteni; Maria Addolorata Mariggiò Journal: Oncol Lett Date: 2011-07-05 Impact factor: 2.967
Authors: Márcia Gaiger de Oliveira; Isabel da Silva Lauxen; Anna Cecília Moraes Chaves; Pantelis Varvaki Rados; Manoel Sant'Ana Filho Journal: Head Neck Pathol Date: 2010-10-30
Authors: Roman C Brands; Mario J J Scheurer; Stefan Hartmann; Axel Seher; Alexander C Kübler; Urs D A Müller-Richter Journal: Oncol Lett Date: 2018-01-12 Impact factor: 2.967
Authors: Rosalia de Necochea-Campion; Chien-Shing Chen; Saied Mirshahidi; Frank D Howard; Nathan R Wall Journal: Cancer Lett Date: 2013-06-18 Impact factor: 8.679